Skip to content
RDL
Network
Ecosystem
Switch app
TR
About
FAQ
Sign in
Get started
LncRNA CASC15 functions as an oncogene by sponging miR-130b-3p in bladder cancer — Xinshuang Yu (2020) | RDL Network
Back
Cite
Save
Save for later
Share
Home
Publications
LncRNA CASC15 functions as an oncogene by sponging miR-130b-3p in bladder cancer
Shared by
Zhong Lin Wang
Beijing Institute of Technology
LncRNA CASC15 functions as an oncogene by sponging miR-130b-3p in bladder cancer
Article
2020
en
Authors
+4 more
XY
Xinshuang Yu
Zhong Lin Wang
Beijing Institute of Technology
CH
Changseok Han
Discussion
(0)
Sign in
to like and join the discussion.
No comments yet. Be the first to comment.
Related publications
Article
2013
Abstract 4204: miR-205 functions as a tumor suppressor in breast cancer by targeting HMGB3.
Ola A. Elgamal
,
Jong Kook Park
,
Thomas D Schmittgen
Article
2017
Downregulation of miR-130b~301b cluster is mediated by aberrant promoter methylation and impairs cellular senescence in prostate cancer
João Carvalho
,
Inês Graça
,
Antonio Gómez
,
Jorge Oliveira
,
Rui Henrique
,
Manel Esteller
,
Cármen Jerónimo
Article
2010
Abstract 2106: Regulation of Rb1 and caspase 3/7 by miR-17-5p, miR-132/-212, and miR-337-3p: Oncogenic role of miRNAs in pancreatic cancer
Jong Kook Park
,
Jinmai Jiang
,
Yuriy Gusev
,
Megan R. Lerner
,
Daniel J. Brackett
,
Thomas D Schmittgen
Article
2018
A multiplatform approach identifies miR-152-3p as a common epigenetically regulated onco-suppressor in prostate cancer targeting TMEM97
João Carvalho
,
Céline S. Gonçalves
,
Inês Graça
,
David Bidarra
,
Eva Pereira-Silva
,
Sofia Salta
,
M.I. Godinho
,
Antonio Gómez
,
Manel Esteller
,
Bruno M. Costa
,
Rui Henrique
,
Cármen Jerónimo
Article
2022
CTCF-Induced lncRNA C5orf66-AS1 Facilitates the Progression of Triple-Negative Breast Cancer via Sponging miR-149-5p to Up-Regulate CTCF and CTNNB1 to Activate Wnt/<i>β</i>-Catenin Pathway
Shuangjiu Zhu
,
Jingjun Sun
,
Xiaoqin Liu
,
Hua Shao
,
Chuanbo Feng
,
Zhong Lin Wang
,
Xinwen Zheng
,
Shaohua Wei
Discussion(0)
No comments yet. Be the first to comment.